413 related articles for article (PubMed ID: 31631821)
21. Molecular hybridization: a powerful tool for multitarget drug discovery.
de Sena Murteira Pinheiro P; Franco LS; Montagnoli TL; Fraga CAM
Expert Opin Drug Discov; 2024 Apr; 19(4):451-470. PubMed ID: 38456452
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
23. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.
Van der Schyf CJ; Mandel S; Geldenhuys WJ; Amit T; Avramovich Y; Zheng H; Fridkin M; Gal S; Weinreb O; Bar Am O; Sagi Y; Youdim MB
Curr Alzheimer Res; 2007 Dec; 4(5):522-36. PubMed ID: 18220515
[TBL] [Abstract][Full Text] [Related]
24. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.
Campos HC; da Rocha MD; Viegas FP; Nicastro PC; Fossaluzza PC; Fraga CA; Barreiro EJ; Viegas C
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):239-50. PubMed ID: 20874702
[TBL] [Abstract][Full Text] [Related]
25. On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective.
Nouri Z; Fakhri S; El-Senduny FF; Sanadgol N; Abd-ElGhani GE; Farzaei MH; Chen JT
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31684142
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
27. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease.
Carrera I; Cacabelos R
Curr Neuropharmacol; 2019; 17(3):295-306. PubMed ID: 30479218
[TBL] [Abstract][Full Text] [Related]
28. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
[TBL] [Abstract][Full Text] [Related]
29. Network Pharmacology: Exploring the Resources and Methodologies.
Muhammad J; Khan A; Ali A; Fang L; Yanjing W; Xu Q; Wei DQ
Curr Top Med Chem; 2018; 18(12):949-964. PubMed ID: 29600765
[TBL] [Abstract][Full Text] [Related]
30. Multi-target compounds acting in the central nervous system designed from natural products.
Chen X; Decker M
Curr Med Chem; 2013; 20(13):1673-85. PubMed ID: 23410166
[TBL] [Abstract][Full Text] [Related]
31. Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases.
Wang ZY; Sreenivasmurthy SG; Song JX; Liu JY; Li M
Drug Discov Today; 2019 Feb; 24(2):595-605. PubMed ID: 30414950
[TBL] [Abstract][Full Text] [Related]
32. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
Pisani L; Catto M; Leonetti F; Nicolotti O; Stefanachi A; Campagna F; Carotti A
Curr Med Chem; 2011; 18(30):4568-87. PubMed ID: 21864289
[TBL] [Abstract][Full Text] [Related]
33. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H
Bautista-Aguilera ÓM; Hagenow S; Palomino-Antolin A; Farré-Alins V; Ismaili L; Joffrin PL; Jimeno ML; Soukup O; Janočková J; Kalinowsky L; Proschak E; Iriepa I; Moraleda I; Schwed JS; Romero Martínez A; López-Muñoz F; Chioua M; Egea J; Ramsay RR; Marco-Contelles J; Stark H
Angew Chem Int Ed Engl; 2017 Oct; 56(41):12765-12769. PubMed ID: 28861918
[TBL] [Abstract][Full Text] [Related]
34. Coumarin: A Privileged Scaffold for the Design and Development of Antineurodegenerative Agents.
Jameel E; Umar T; Kumar J; Hoda N
Chem Biol Drug Des; 2016 Jan; 87(1):21-38. PubMed ID: 26242562
[TBL] [Abstract][Full Text] [Related]
35. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis.
León R; Marco-Contelles J
Curr Med Chem; 2011; 18(4):552-76. PubMed ID: 21143111
[TBL] [Abstract][Full Text] [Related]
36. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
Jeřábek J; Uliassi E; Guidotti L; Korábečný J; Soukup O; Sepsova V; Hrabinova M; Kuča K; Bartolini M; Peña-Altamira LE; Petralla S; Monti B; Roberti M; Bolognesi ML
Eur J Med Chem; 2017 Feb; 127():250-262. PubMed ID: 28064079
[TBL] [Abstract][Full Text] [Related]
37. CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease.
Ambure P; Roy K
Curr Drug Targets; 2017; 18(5):522-533. PubMed ID: 26343117
[TBL] [Abstract][Full Text] [Related]
38.
Banjare P; Wamanrao Matore B; Murmu A; Kumar V; Singh J; Roy PP
Curr Top Med Chem; 2023; 23(29):2765-2791. PubMed ID: 37723952
[TBL] [Abstract][Full Text] [Related]
39. Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
Zhou J; Jiang X; He S; Jiang H; Feng F; Liu W; Qu W; Sun H
J Med Chem; 2019 Oct; 62(20):8881-8914. PubMed ID: 31082225
[TBL] [Abstract][Full Text] [Related]
40. Catalpol: a potential therapeutic for neurodegenerative diseases.
Jiang B; Shen RF; Bi J; Tian XS; Hinchliffe T; Xia Y
Curr Med Chem; 2015; 22(10):1278-91. PubMed ID: 25620103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
